Table of Contents Author Guidelines Submit a Manuscript
Obstetrics and Gynecology International
Volume 2013, Article ID 173184, 11 pages
http://dx.doi.org/10.1155/2013/173184
Review Article

Uterine Fibroids: Pathogenesis and Interactions with Endometrium and Endomyometrial Junction

1Woman's Health Sciences Department, Faculty of Medicine, Polytechnic University of Marche, Via Corridoni 11, 60123 Ancona, Italy
2Department of Gynaecological Sciences and Human Reproduction, University of Padova, Via Giustiniani 3, 35128 Padova, Italy
3Department of Experimental and Clinical Medicine, Faculty of Medicine, Polytechnic University of Marche, Via Tronto 10/a, 60126 Ancona, Italy
4Department of Obstetrics and Gynecology, Federal University of Minas Gerais and National Institute of Hormones and Women’s Health, 30130-100 Belo Horizonte, MG, Brazil

Received 28 February 2013; Revised 10 June 2013; Accepted 13 August 2013

Academic Editor: Hilary Critchley

Copyright © 2013 Andrea Ciavattini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Bowden, J. Skorupski, E. Kovanci, and A. Rajkovic, “Detection of novel copy number variants in uterine leiomyomas using high-resolution SNP arrays,” Molecular Human Reproduction, vol. 15, no. 9, pp. 563–568, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. K. Laughlin, J. C. Schroeder, and D. D. Baird, “New directions in the epidemiology of uterine fibroids,” Seminars in Reproductive Medicine, vol. 28, no. 3, pp. 204–217, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. S. F. Cramer and A. Patel, “The frequency of uterine leiomyomas,” American Journal of Clinical Pathology, vol. 94, no. 4, pp. 435–438, 1990. View at Google Scholar · View at Scopus
  4. M. Payson, P. Leppert, and J. Segars, “Epidemiology of myomas,” Obstetrics and Gynecology Clinics of North America, vol. 33, no. 1, pp. 1–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. D. Peddada, S. K. Laughlin, K. Miner et al., “Growth of uterine leiomyomata among premenopausal black and white women,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 50, pp. 19887–19892, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. K. Lobel, P. Somasundaram, and C. C. Morton, “The genetic heterogeneity of uterine leiomyomata,” Obstetrics and Gynecology Clinics of North America, vol. 33, no. 1, pp. 13–39, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Wei, L. Chiriboga, A. A. Arslan, J. Melamed, H. Yee, and K. Mittal, “Ethnic differences in expression of the dysregulated proteins in uterine leiomyomata,” Human Reproduction, vol. 21, no. 1, pp. 57–67, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Wei, L. Chiriboga, and K. Mittal, “Expression profile of the tumorigenic factors associated with tumor size and sex steroid hormone status in uterine leiomyomata,” Fertility and Sterility, vol. 84, no. 2, pp. 474–484, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Wolańska and E. Bańkowski, “Transforming growth factor β and platelet-derived growth factor in human myometrium and in uterine leiomyomas at various stages of tumour growth,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 130, no. 2, pp. 238–244, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Wang, X. Zhang, L. Obijuru et al., “A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas,” Genes Chromosomes and Cancer, vol. 46, no. 4, pp. 336–347, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Marshall, D. Spiegelman, R. L. Barbieri et al., “Variation in the incidence of uterine leiomyoma among premenopausal women by age and race,” Obstetrics and Gynecology, vol. 90, no. 6, pp. 967–973, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. K. H. Kjerulff, P. Langenberg, J. D. Seidman, P. D. Stolley, and G. M. Guzinski, “Uterine leiomyomas: racial differences in severity, symptoms and age at diagnosis,” Journal of Reproductive Medicine for the Obstetrician and Gynecologist, vol. 41, no. 7, pp. 483–490, 1996. View at Google Scholar · View at Scopus
  13. G. P. Flake, J. Andersen, and D. Dixon, “Etiology and pathogenesis of uterine leiomyomas: a review,” Environmental Health Perspectives, vol. 111, no. 8, pp. 1037–1054, 2003. View at Google Scholar · View at Scopus
  14. W. H. Parker, “Etiology, symptomatology, and diagnosis of uterine myomas,” Fertility and Sterility, vol. 87, no. 4, pp. 725–736, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. D. D. Baird, M. C. Hill, J. M. Schectman, and B. W. Hollis, “Vitamin D and the risk of uterine fibroids,” Epidemiology, vol. 24, pp. 447–453, 2013. View at Google Scholar
  16. M. Sabry, S. K. Halder, A. S. Allah, E. Roshdy, V. Rajaratnam, and A. Al-Hendy, “Serum vitamin D3 level inversely correlates with uterine fibroid volume in different ethnic groups: a cross-sectional observational study,” International Journal of Women's Health, vol. 5, pp. 93–100, 2013. View at Google Scholar
  17. P. C. Leppert, W. H. Catherino, and J. H. Segars, “A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays,” American Journal of Obstetrics and Gynecology, vol. 195, no. 2, pp. 415–420, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. S. M. Schwartz, L. M. Marshall, and D. D. Baird, “Epidemiologic contributions to understanding the etiology of uterine leiomyomata,” Environmental Health Perspectives, vol. 108, supplement 5, pp. 821–827, 2000. View at Google Scholar · View at Scopus
  19. E. M. Vikhlyaeva, “Familial predisposition to uterine leiomyomas,” International Journal of Gynecology and Obstetrics, vol. 51, no. 2, pp. 127–131, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. T. M. Saldana, M. Moshesh, and D. D. Baird, “Self-reported family history of leiomyoma: not a reliable marker of high risk,” Annals of Epidemiology, vol. 23, no. 5, pp. 286–290, 2013. View at Google Scholar
  21. R. K. Ross, M. C. Pike, and M. P. Vessey, “Risk factors for uterine fibroids: reduced risk associated with oral contraceptives,” The British Medical Journal, vol. 293, no. 6543, pp. 359–362, 1986. View at Google Scholar · View at Scopus
  22. S. A. Shikora, J. M. Niloff, B. R. Bistrian, R. A. Forse, and G. L. Blackburn, “Relationship between obesity and uterine leiomyomata,” Nutrition, vol. 7, no. 4, pp. 251–255, 1991. View at Google Scholar · View at Scopus
  23. S. Nair and A. Al-Hendy, “Adipocytes enhance the proliferation of human leiomyoma cells via TNF-α proinflammatory cytokine,” Reproductive Sciences, vol. 18, no. 12, pp. 1186–1192, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. F. Chiaffarino, F. Parazzini, C. La Vecchia, L. Chatenoud, E. Di Cintio, and S. Marsico, “Diet and uterine myomas,” Obstetrics and Gynecology, vol. 94, no. 3, pp. 395–398, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Wyshak, R. E. Frisch, and N. L. Albright, “Lower prevalence of benign diseases of the breast and benign tumours of the reproductive system among former college athletes compared to non-athletes,” British Journal of Cancer, vol. 54, no. 5, pp. 841–845, 1986. View at Google Scholar · View at Scopus
  26. R. L. Barbieri, P. M. McShane, and K. J. Ryan, “Constituents of cigarette smoke inhibit human granulosa cell aromatase,” Fertility and Sterility, vol. 46, no. 2, pp. 232–236, 1986. View at Google Scholar · View at Scopus
  27. J. J. Michnovicz, R. J. Hershcopf, and H. Naganuma, “Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking,” The New England Journal of Medicine, vol. 315, no. 21, pp. 1305–1309, 1986. View at Google Scholar · View at Scopus
  28. M. Daniel, A. D. Martin, and D. T. Drinkwater, “Cigarette smoking, steroid hormones, and bone mineral density in young women,” Calcified Tissue International, vol. 50, no. 4, pp. 300–305, 1992. View at Publisher · View at Google Scholar · View at Scopus
  29. A. J. Tiltman, “The effect of progestins on the mitotic activity of uterine fibromyomas,” International Journal of Gynecological Pathology, vol. 4, no. 2, pp. 89–96, 1985. View at Google Scholar · View at Scopus
  30. F. Parazzini, E. Negri, C. La Vecchia, L. Chatenoud, E. Ricci, and P. Guarnerio, “Reproductive factors and risk of uterine fibroids,” Epidemiology, vol. 7, no. 4, pp. 440–442, 1996. View at Google Scholar · View at Scopus
  31. P. Lumbiganon, S. Rugpao, S. Phandhu-fung, M. Laopaiboon, N. Vudhikamraksa, and Y. Werawatakul, “Protective effect of depot-medroxyprogesterone acetate on surgically treated uterine leiomyomas: a multicentre case-control study,” British Journal of Obstetrics and Gynaecology, vol. 103, no. 9, pp. 909–914, 1996. View at Google Scholar · View at Scopus
  32. D. D. Baird and D. B. Dunson, “Why is parity protective for uterine fibroids?” Epidemiology, vol. 14, no. 2, pp. 247–250, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Palomba, T. Sena, M. Morelli, R. Noia, F. Zullo, and P. Mastrantonio, “Effect of different doses of progestin on uterine leiomyomas in postmenopausal women,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 102, no. 2, pp. 199–201, 2002. View at Publisher · View at Google Scholar · View at Scopus
  34. D. W. Cramer, “Epidemiology of myomas,” Seminars in Reproductive Endocrinology, vol. 10, no. 4, pp. 320–324, 1992. View at Google Scholar · View at Scopus
  35. M. S. Rein, “Advances in uterine leiomyoma research: the progesterone hypothesis,” Environmental Health Perspectives, vol. 108, no. 5, pp. 791–793, 2000. View at Google Scholar · View at Scopus
  36. P. A. Richards and A. J. Tiltman, “Anatomical variation of the oestrogen receptor in the non-neoplastic myometrium of fibromyomatous uteri,” Virchows Archiv, vol. 428, no. 6, pp. 347–351, 1996. View at Google Scholar · View at Scopus
  37. E. A. Stewart and R. A. Nowak, “Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era,” Human Reproduction Update, vol. 2, no. 4, pp. 295–306, 1996. View at Google Scholar · View at Scopus
  38. D. Dixon, G. P. Flake, A. B. Moore et al., “Cell proliferation and apoptosis in human uterine leiomyomas and myometria,” Virchows Archiv, vol. 441, no. 1, pp. 53–62, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. V. Lindner and M. A. Reidy, “Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 9, pp. 3739–3743, 1991. View at Google Scholar · View at Scopus
  40. R. S. Mangrulkar, M. Ono, M. Ishikawa, S. Takashima, M. Klagsbrun, and R. A. Nowak, “Isolation and characterization of heparin-binding growth factors in human leiomyomas and normal myometrium,” Biology of Reproduction, vol. 53, no. 3, pp. 636–646, 1995. View at Publisher · View at Google Scholar · View at Scopus
  41. K. L. Gross and C. C. Morton, “Genetics and the development of fibroids,” Clinical Obstetrics and Gynecology, vol. 44, pp. 335–349, 2001. View at Google Scholar
  42. J. C. Hodge, K. T. Cuenco, K. L. Huyck et al., “Uterine leiomyomata and decreased height: a common HMGA2 predisposition allele,” Human Genetics, vol. 125, no. 3, pp. 257–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. G. J. Gattas, B. J. Quade, R. A. Nowak, and C. C. Morton, “HMGIC expression in human adult and fetal tissues and in uterine leiomyomata,” Genes, Chromosomes and Cancer, vol. 25, pp. 316–322, 1999. View at Google Scholar
  44. D. N. Markowski, B. M. Helmke, G. Belge et al., “HMGA2 and p14Arf: major roles in cellular senescence of fibroids and therapeutic implications,” Anticancer Research, vol. 31, no. 3, pp. 753–761, 2011. View at Google Scholar · View at Scopus
  45. S. Sudarshan, P. A. Pinto, L. Neckers, and W. M. Linehan, “Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer—a distinct form of hereditary kidney cancer,” Nature Clinical Practice Urology, vol. 4, no. 2, pp. 104–110, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. V. Uliana, E. Marcocci, M. Mucciolo et al., “Alport syndrome and leiomyomatosis: the first deletion extending beyond COL4A6 intron 2,” Pediatric Nephrology, vol. 26, no. 5, pp. 717–724, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. P. Cha, A. Takahashi, N. Hosono et al., “A genome-wide association study identifies three loci associated with susceptibility to uterine fibroids,” Nature Genetics, vol. 43, no. 5, pp. 447–451, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Rogers, J. Norian, M. Malik et al., “Mechanical homeostasis is altered in uterine leiomyoma,” American Journal of Obstetrics and Gynecology, vol. 198, no. 4, pp. 474.e1–474.e11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Mäkinen, M. Mehine, J. Tolvanen et al., “MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas,” Science, vol. 334, no. 6053, pp. 252–255, 2011. View at Publisher · View at Google Scholar · View at Scopus
  50. E. M. Je, M. R. Kim, K. O. Min, N. J. Yoo, and S. H. Lee, “Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors,” International Journal of Cancer, vol. 131, no. 6, pp. E1044–E1047, 2012. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Pérot, S. Croce, A. Ribeiro et al., “MED12 alterations in both human benign and malignant uterine soft tissue tumors,” PLoS One, vol. 7, no. 6, Article ID e40015, 2012. View at Google Scholar
  52. S. Kim, X. Xu, A. Hecht, and T. G. Boyer, “Mediator is a transducer of Wnt/β-catenin signaling,” The Journal of Biological Chemistry, vol. 281, no. 20, pp. 14066–14075, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. P. P. Rocha, M. Scholze, W. Bleiß, and H. Schrewe, “Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling,” Development, vol. 137, no. 16, pp. 2723–2731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. J. Zavadil, H. Ye, Z. Liu et al., “Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas,” PLoS ONE, vol. 5, no. 8, Article ID e12362, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Lin, W. Xia, J. C. Wang et al., “β-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 8, pp. 4262–4266, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. Q. Qiao, M. Ramadani, S. Gansauge et al., “Reduced membranous and ectopic cytoplasmic expression of beta-catenin correlate with cyclin D1 overexpression and poor prognosis in pancreatic cancer,” International Journal of Cancer, vol. 95, pp. 194–197, 2001. View at Google Scholar
  57. E. A. Kogan, V. E. Ignatova, T. N. Rukhadze, E. A. Kudrina, and A. I. Ischenko, “A role of growth factors in development of various histological types of uterine leiomyoma,” Arkhiv Patologii, vol. 67, no. 3, pp. 34–38, 2005. View at Google Scholar · View at Scopus
  58. J. M. Norian, M. Malik, C. Y. Parker et al., “Transforming Growth Factor β3 regulates the versican variants in the extracellular matrix-rich uterine leiomyomas,” Reproductive Sciences, vol. 16, no. 12, pp. 1153–1164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. M. Malik, J. Webb, and W. H. Catherino, “Retinoic acid treatment of human leiomyoma cells transformed the cell phenotype to one strongly resembling myometrial cells,” Clinical Endocrinology, vol. 69, no. 3, pp. 462–470, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. J. M. Norian, C. M. Owen, J. Taboas et al., “Characterization of tissue biomechanics and mechanical signaling in uterine leiomyoma,” Matrix Biology, vol. 31, no. 1, pp. 57–65, 2012. View at Publisher · View at Google Scholar · View at Scopus
  61. H. Asada, Y. Yamagata, T. Taketani et al., “Potential link between estrogen receptor-α gene hypomethylation and uterine fibroid formation,” Molecular Human Reproduction, vol. 14, no. 9, pp. 539–545, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Yamagata, R. Maekawa, H. Asada et al., “Aberrant DNA methylation status in human uterine leiomyoma,” Molecular Human Reproduction, vol. 15, no. 4, pp. 259–267, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. D. P. Bartel, “MicroRNAs: genomics, biogenesis, mechanism, and function,” Cell, vol. 116, no. 2, pp. 281–297, 2004. View at Publisher · View at Google Scholar · View at Scopus
  64. E. A. Miska, “How microRNAs control cell division, differentiation and death,” Current Opinion in Genetics and Development, vol. 15, no. 5, pp. 563–568, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. E. E. Marsh, Z. Lin, P. Yin, M. Milad, D. Chakravarti, and S. E. Bulun, “Differential expression of microRNA species in human uterine leiomyoma versus normal myometrium,” Fertility and Sterility, vol. 89, no. 6, pp. 1771–1776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. C. Benassayag, M. J. Leroy, V. Rigourd et al., “Estrogen receptors (ERα/ERβ) in normal and pathological growth of the human myometrium: pregnancy and leiomyoma,” American Journal of Physiology, vol. 276, no. 6, pp. E1112–E1118, 1999. View at Google Scholar · View at Scopus
  67. K. A. Kovács, A. Oszter, P. M. Göcze, J. L. Környei, and I. Szabó, “Comparative analysis of cyclin D1 and oestrogen receptor (α and β) levels in human leiomyoma and adjacent myometrium,” Molecular Human Reproduction, vol. 7, no. 11, pp. 1085–1091, 2001. View at Google Scholar · View at Scopus
  68. A. Olmos Grings, V. Lora, G. Dias Ferreira, I. Simoni Brum, H. Von Eye Corleta, and E. Capp, “Protein expression of estrogen receptors α and β and aromatase in myometrium and uterine leiomyoma,” Gynecologic and Obstetric Investigation, vol. 73, no. 2, pp. 113–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. H. Ishikawa, K. Ishi, V. Ann Serna, R. Kakazu, S. E. Bulun, and T. Kurita, “Progesterone is essential for maintenance and growth of uterine leiomyoma,” Endocrinology, vol. 151, no. 6, pp. 2433–2442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. H. Ishikawa, K. Ishi, V. Ann Serna, R. Kakazu, S. E. Bulun, and T. Kurita, “Progesterone is essential for maintenance and growth of uterine leiomyoma,” Endocrinology, vol. 151, no. 6, pp. 2433–2442, 2010. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Barbarisi, O. Petillo, A. Di Lieto et al., “17-beta estradiol elicits an autocrine leiomyoma cell proliferation: evidence for a stimulation of protein kinase-dependent pathway,” Journal of Cellular Physiology, vol. 186, no. 3, pp. 414–424, 2001. View at Google Scholar
  72. P. Ciarmela, E. Bloise, P. C. Gray et al., “Activin-A and myostatin response and steroid regulation in human myometrium: disruption of their signalling in uterine fibroid,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 755–765, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. Y. Shimomura, H. Matsuo, T. Samoto, and T. Maruo, “Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 6, pp. 2192–2198, 1998. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Matsuo, T. Maruo, and T. Samoto, “Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone,” Journal of Clinical Endocrinology and Metabolism, vol. 82, no. 1, pp. 293–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  75. E. N. Nierth-Simpson, M. M. Martin, T. Chiang et al., “Human uterine smooth muscle and leiomyoma cells differ in their rapid 17/J-estradiol signaling: implications for proliferation,” Endocrinology, vol. 150, no. 5, pp. 2436–2445, 2009. View at Publisher · View at Google Scholar · View at Scopus
  76. S. Park, S. Ramachandran, S. Kwon et al., “Upregulation of ATP-sensitive potassium channels for estrogen-mediated cell proliferation in human uterine leiomyoma cells,” Gynecological Endocrinology, vol. 24, no. 5, pp. 250–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Kastner, A. Krust, B. Turcotte et al., “Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B,” The EMBO Journal, vol. 9, no. 5, pp. 1603–1614, 1990. View at Google Scholar · View at Scopus
  78. T. Maruo, N. Ohara, S. Yoshida et al., “Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine system,” Contraception, vol. 82, no. 5, pp. 435–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. J. J. Kim and E. C. Sefton, “The role of progesterone signaling in the pathogenesis of uterine leiomyoma,” Molecular and Cellular Endocrinology, vol. 358, no. 2, pp. 223–231, 2011. View at Google Scholar
  80. O. Sadan, B. Van Iddekinge, and C. J. Van Gelderen, “Oestrogen and progesterone receptor concentrations in leiomyoma and normal myometrium,” Annals of Clinical Biochemistry, vol. 24, no. 3, pp. 263–267, 1987. View at Google Scholar · View at Scopus
  81. G. Marelli, A. M. Codegoni, and A. Bizzi, “Estrogen and progesterone receptors in leiomyomas and normal uterine tissues during reproductive life,” Acta Europaea Fertilitatis, vol. 20, no. 1, pp. 19–22, 1989. View at Google Scholar · View at Scopus
  82. D. D. Brandon, C. L. Bethea, E. Y. Strawn et al., “Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas,” American Journal of Obstetrics and Gynecology, vol. 169, no. 1, pp. 78–85, 1993. View at Google Scholar · View at Scopus
  83. B. Viville, D. S. Charnock-Jones, A. M. Sharkey, B. Wetzka, and S. K. Smith, “Distribution of the A and B forms of the progesterone receptor messenger ribonucleic acid and protein in uterine leiomyomata and adjacent myometrium,” Human Reproduction, vol. 12, no. 4, pp. 815–822, 1997. View at Publisher · View at Google Scholar · View at Scopus
  84. Z. Ying and Z. Weiyuan, “Dual actions of progesterone on uterine leiomyoma correlate with the ratio of progesterone receptor A:B,” Gynecological Endocrinology, vol. 25, no. 8, pp. 520–523, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Fujimota, R. Hirose, S. Ichigo, H. Sakaguchi, Y. Li, and T. Tamaya, “Expression of progesterone receptor form A and B mRNAs in uterine leiomyoma,” Tumor Biology, vol. 19, no. 2, pp. 126–131, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Arici and I. Sozen, “Transforming growth factor-β3 is expressed at high levels in leiomyoma where it stimulates fibronectin expression and cell proliferation,” Fertility and Sterility, vol. 73, no. 5, pp. 1006–1011, 2000. View at Publisher · View at Google Scholar · View at Scopus
  87. O. Kurachi, H. Matsuo, T. Samoto, and T. Maruo, “Tumor necrosis factor-α expression in human uterine leiomyoma and its down-regulation by progesterone,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 2275–2280, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. P. Yin, Z. Lin, Y. Cheng et al., “Progesterone receptor regulates Bcl-2 gene expression through direct binding to its promoter region in uterine leiomyoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 11, pp. 4459–4466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  89. X. Luo, P. Yin, S. Reierstad et al., “Progesterone and mifepristone regulate L-type amino acid transporter 2 and 4F2 heavy chain expression in uterine leiomyoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 11, pp. 4533–4539, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. P. Yin, Z. Lin, S. Reierstad et al., “Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells,” Cancer Research, vol. 70, no. 4, pp. 1722–1730, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. P. Ciarmela, M. S. Islam, F. M. Reis et al., “Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications,” Human Reproduction Update, vol. 17, no. 6, Article ID dmr031, pp. 772–790, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. C. A. Anania, E. A. Stewart, B. J. Quade, J. A. Hill, and R. A. Nowak, “Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding,” Molecular Human Reproduction, vol. 3, no. 8, pp. 685–691, 1997. View at Google Scholar · View at Scopus
  93. T. Hong, Y. Shimada, S. Uchida et al., “Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma,” International Journal of Molecular Medicine, vol. 8, no. 2, pp. 141–148, 2001. View at Google Scholar · View at Scopus
  94. S. Arita, F. Kikkawa, H. Kajiyama et al., “Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma,” International Journal of Gynecological Cancer, vol. 15, no. 2, pp. 329–336, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. M. J. Rossi, N. Chegini, and B. J. Masterson, “Presence of epidermal growth factor, platelet-derived growth factor, and their receptors in human myometrial tissue and smooth muscle cells: their action in smooth muscle cells in vitro,” Endocrinology, vol. 130, no. 3, pp. 1716–1727, 1992. View at Publisher · View at Google Scholar · View at Scopus
  96. Y. Ren, H. Yin, R. Tian et al., “Different effects of epidermal growth factor on smooth muscle cells derived from human myometrium and from leiomyoma,” Fertility and Sterility, vol. 96, no. 4, pp. 1015.e1–1020.e1, 2011. View at Publisher · View at Google Scholar · View at Scopus
  97. Y. M. Fayed, J. C. M. Tsibris, P. W. Langenberg, and A. L. Robertson Jr., “Human uterine leiomyoma cells: binding and growth responses to epidermal growth factor, platelet-derived growth factor, and insulin,” Laboratory Investigation, vol. 60, no. 1, pp. 30–37, 1989. View at Google Scholar · View at Scopus
  98. A. Arici and I. Sozen, “Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-β1 in human myometrium and leiomyoma,” American Journal of Obstetrics and Gynecology, vol. 188, no. 1, pp. 76–83, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. M. Liang, H. Wang, Y. Zhang, S. Lu, and Z. Wang, “Expression and functional analysis of platelet-derived growth factor in uterine leiomyomata,” Cancer Biology and Therapy, vol. 5, no. 1, pp. 28–33, 2006. View at Google Scholar · View at Scopus
  100. G. Suo, Y. Jiang, B. Cowan, and J. Y. J. Wang, “Platelet-derived growth factor C is upregulated in human uterine fibroids and regulates uterine smooth muscle cell growth,” Biology of Reproduction, vol. 81, no. 4, pp. 749–758, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. D. S. Joseph, M. Malik, S. Nurudeen, and W. H. Catherino, “Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor β-3,” Fertility and Sterility, vol. 93, no. 5, pp. 1500–1508, 2010. View at Publisher · View at Google Scholar · View at Scopus
  102. L. Ding, J. Xu, X. Luo, and N. Chegini, “Gonadotropin releasing hormone and transforming growth factor β activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator inhibitor-1 expression in leiomyoma and myometrial smooth muscle cells,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5549–5557, 2004. View at Publisher · View at Google Scholar · View at Scopus
  103. L. Yu, K. Saile, C. D. Swartz et al., “Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas,” Molecular Medicine, vol. 14, no. 5-6, pp. 264–275, 2008. View at Google Scholar
  104. Z. Gao, H. Matsuo, Y. Wang, S. Nakago, and T. Maruo, “Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5593–5599, 2001. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Ciarmela, E. Wiater, and W. Vale, “Activin-A in myometrium: characterization of the actions on myometrial cells,” Endocrinology, vol. 149, no. 5, pp. 2506–2516, 2008. View at Publisher · View at Google Scholar · View at Scopus
  106. P. Ciarmela, E. Wiater, S. M. Smith, and W. Vale, “Presence, actions, and regulation of myostatin in rat uterus and myometrial cells,” Endocrinology, vol. 150, no. 2, pp. 906–914, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. E. C. Weir, D. L. Goad, A. G. Daifotis, W. J. Burtis, B. E. Dreyer, and R. A. Nowak, “Relative overexpression of the parathyroid hormone-related protein gene in human leiomyomas,” Journal of Clinical Endocrinology and Metabolism, vol. 78, no. 3, pp. 784–789, 1994. View at Publisher · View at Google Scholar · View at Scopus
  108. M. Yoshida, A. Ohtsuru, T. Samejima et al., “Involvement of parathyroid hormone-related peptide in cell proliferation activity of human uterine leiomyomas,” Endocrine Journal, vol. 46, no. 1, pp. 81–90, 1999. View at Google Scholar · View at Scopus
  109. B. Gellersen, A. Bonhoff, N. Hunt, and H. G. Bohnet, “Decidual-type prolactin expression by the human myometrium,” Endocrinology, vol. 129, no. 1, pp. 158–168, 1991. View at Google Scholar · View at Scopus
  110. D. J. Austin, R. A. Nowak, and E. A. Stewart, “Onapristone suppresses prolactin production in explant cultures of leiomyoma,” Gynecologic and Obstetric Investigation, vol. 47, no. 4, pp. 268–271, 1999. View at Publisher · View at Google Scholar · View at Scopus
  111. F. Pekonen, T. Nyman, and E.-M. Rutanen, “Differential expression of mRNAs for endothelin-related proteins in human endometrium, myometrium and leiomyoma,” Molecular and Cellular Endocrinology, vol. 103, no. 1-2, pp. 165–170, 1994. View at Publisher · View at Google Scholar · View at Scopus
  112. P. Robin, S. Chouayekh, C. Bole-Feysot, D. Leiber, and Z. Tanfin, “Contribution of phospholipase D in endothelin-1-mediated extracellular signal-regulated kinase activation and proliferation in rat uterine leiomyoma cells,” Biology of Reproduction, vol. 72, no. 1, pp. 69–77, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. A. Horiuchi, T. Nikaido, T. Yoshizawa et al., “HCG promotes proliferation of uterine leiomyomal cells more strongly than that of myometrial smooth muscle cells in vitro,” Molecular Human Reproduction, vol. 6, no. 6, pp. 523–528, 2000. View at Google Scholar · View at Scopus
  114. S.-J. Tsai, S.-J. Lin, Y.-M. Cheng, H.-M. Chen, and L.-Y. C. Wing, “Erratum: Expression and functional analysis of pituitary tumor transforming growth factor-1 in uterine leiomyomas (The Journal of Clinical Endocrinology and Metabolism (2005) 90 (3715-3723)),” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 9, p. 5233, 2005. View at Google Scholar · View at Scopus
  115. M. Suzuki, S. Takamizawa, K. Nomaguchi et al., “Erythropoietin synthesis by tumour tissues in a patient with uterine myoma and erythrocytosis,” British Journal of Haematology, vol. 113, no. 1, pp. 49–51, 2001. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Hatthachote and J. I. Gillespie, “Complex interactions between sex steroids and cytokines in the human pregnant myometrium: evidence for an autocrine signaling system at term,” Endocrinology, vol. 140, no. 6, pp. 2533–2540, 1999. View at Publisher · View at Google Scholar · View at Scopus
  117. K. V. Litovkin, V. P. Domenyuk, V. V. Bubnov, and V. N. Zaporozhan, “Interleukin-6-174G/C polymorphism in breast cancer and uterine leiomyoma patients: a population-based case control study,” Experimental Oncology, vol. 29, no. 4, pp. 295–298, 2007. View at Google Scholar · View at Scopus
  118. T. L. Bonfield, J. R. Panuska, M. W. Konstan et al., “Inflammatory cytokines in cystic fibrosis lungs,” American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 6 I, pp. 2111–2118, 1995. View at Google Scholar · View at Scopus
  119. B. Mehrad, M. P. Keane, and R. M. Strieter, “Chemokines as mediators of angiogenesis,” Thrombosis and Haemostasis, vol. 97, no. 5, pp. 755–762, 2007. View at Publisher · View at Google Scholar · View at Scopus
  120. H. E. Broxmeyer, “Chemokines in hematopoiesis,” Current Opinion in Hematology, vol. 15, no. 1, pp. 49–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  121. I. Sozen, D. L. Olive, and A. Arici, “Expression and hormonal regulation of monocyte chemotactic protein-1 in myometrium and leiomyomata,” Fertility and Sterility, vol. 69, no. 6, pp. 1095–1102, 1998. View at Publisher · View at Google Scholar · View at Scopus
  122. L. M. Senturk, I. Sozen, L. Gutierrez, and A. Arici, “Interleukin 8 production and interleukin 8 receptor expression in human myometrium and leiomyoma,” American Journal of Obstetrics and Gynecology, vol. 184, no. 4, pp. 559–566, 2001. View at Publisher · View at Google Scholar · View at Scopus
  123. S. F. Cramer, P. M. Newcomb, and T. A. Bonfiglio, “Myometrial dysplasia (atypical myometrial hyperplasia),” Human Pathology, vol. 38, no. 4, pp. 652–655, 2007. View at Publisher · View at Google Scholar · View at Scopus
  124. S. F. Cramer and A. L. Robertson Jr, “The origin of uterine leiomyomas,” in The Extracellular Matrix of the Uterus, Cervix, and Fetal Membranes, P. C. Leppert and J. F. Woessner, Eds., pp. 213–223, Perinatology Press, Ithaca, NY, USA, 1991. View at Google Scholar
  125. M. Malik, J. Norian, D. McCarthy-Keith, J. Britten, and W. H. Catherino, “Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women,” Seminars in Reproductive Medicine, vol. 28, no. 3, pp. 169–179, 2010. View at Publisher · View at Google Scholar · View at Scopus
  126. M. Wolańska, K. Sobolewski, M. Drozdzewicz, and E. Bańkowski, “Extracellular matrix components in uterine leiomyoma and their alteration during the tumour growth,” Molecular and Cellular Biochemistry, vol. 189, no. 1-2, pp. 145–152, 1998. View at Google Scholar · View at Scopus
  127. A. G. A. Berto, S. M. Oba, Y. M. Michelacci, and L. O. Sampaio, “Galactosaminoglycans from normal myometrium and leiomyoma,” Brazilian Journal of Medical and Biological Research, vol. 34, no. 5, pp. 633–637, 2001. View at Google Scholar · View at Scopus
  128. B. Bodner-Adler, K. Bodner, O. Kimberger, K. Czerwenka, S. Leodolter, and K. Mayerhofer, “Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: an immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma,” Journal of the Society for Gynecologic Investigation, vol. 11, no. 3, pp. 182–186, 2004. View at Publisher · View at Google Scholar · View at Scopus
  129. M. Bogusiewicz, M. Stryjecka-Zimmer, K. Postawski, A. J. Jakimiuk, and T. Rechberger, “Activity of matrix metalloproteinase-2 and -9 and contents of their tissue inhibitors in uterine leiomyoma and corresponding myometrium,” Gynecological Endocrinology, vol. 23, no. 9, pp. 541–546, 2007. View at Publisher · View at Google Scholar · View at Scopus
  130. H. Hricak, C. Alpers, L. E. Crooks, and P. E. Sheldon, “Magnetic resonance imaging of the female pelvis: initial experience,” American Journal of Roentgenology, vol. 141, no. 6, pp. 1119–1128, 1983. View at Google Scholar · View at Scopus
  131. A. Tocci, E. Greco, and F. M. Ubaldi, “Adenomyosis and endometrial-subendometrial myometrium unit disruption disease are two different entities,” Reproductive BioMedicine Online, vol. 17, no. 2, pp. 285–291, 2008. View at Google Scholar · View at Scopus
  132. J. J. Brosens, F. G. Barker, and N. M. DeSouza, “Myometrial zonal differentiation and uterine junctional zone hyperplasia in the non-pregnant uterus,” Human Reproduction Update, vol. 4, no. 5, pp. 496–502, 1998. View at Publisher · View at Google Scholar · View at Scopus
  133. Practice Committee of the American Society for Reproductive Medicine, “Myomas and reproductive function,” Fertility and Sterility, vol. 82, 1, pp. S111–S116, 2004. View at Google Scholar
  134. V. C. Buttram Jr. and R. C. Reiter, “Uterine leiomyomata: etiology, symptomatology, and management,” Fertility and Sterility, vol. 36, no. 4, pp. 433–445, 1981. View at Google Scholar · View at Scopus
  135. J. M. Berman, “Intrauterine adhesions,” Seminars in Reproductive Medicine, vol. 26, no. 4, pp. 349–355, 2008. View at Publisher · View at Google Scholar · View at Scopus
  136. C. Davies, M. Gibson, E. M. Holt, and E. P. H. Torrie, “Amenorrhoea secondary to endometrial ablation and Asherman's syndrome following uterine artery embolization,” Clinical Radiology, vol. 57, no. 4, pp. 317–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  137. A. A. Hare and K. S. Olah, “Pregnancy following endometrial ablation: a review article,” Journal of Obstetrics and Gynaecology, vol. 25, no. 2, pp. 108–114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  138. A. Magos, “Hysteroscopic treatment of Asherman's syndrome,” Reproductive BioMedicine Online, vol. 4, 3, pp. 46–51, 2002. View at Google Scholar
  139. S. F. Cramer, L. Mann, E. Calianese, J. Daley, and K. Williamson, “Association of seedling myomas with myometrial hyperplasia,” Human Pathology, vol. 40, no. 2, pp. 218–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  140. L. M. Scoutt, S. D. Flynn, D. J. Luthringer, T. R. McCauley, and S. M. McCarthy, “Junctional zone of the uterus: correlation of MR imaging and histologic examination of hysterectomy specimens,” Radiology, vol. 179, no. 2, pp. 403–407, 1991. View at Google Scholar · View at Scopus
  141. C. Bulletti, D. De Ziegler, V. Polli, and C. Flamigni, “The role of leiomyomas in infertility,” Journal of the American Association of Gynecologic Laparoscopists, vol. 6, no. 4, pp. 441–445, 1999. View at Google Scholar · View at Scopus
  142. P. A. Richards, P. D. G. Richards, and A. J. Tiltman, “The ultrastructure of fibromyomatous myometrium and its relationship to infertility,” Human Reproduction Update, vol. 4, no. 5, pp. 520–525, 1998. View at Publisher · View at Google Scholar · View at Scopus
  143. O. Yoshino, T. Hayashi, Y. Osuga et al., “Decreased pregnancy rate is linked to abnormal uterine peristalsis caused by intramural fibroids,” Human Reproduction, vol. 25, no. 10, pp. 2475–2479, 2010. View at Publisher · View at Google Scholar · View at Scopus
  144. T. Inoue, H. Kanzaki, M. Iwai et al., “Tumour necrosis factor α inhibits in-vitro decidualization of human endometrial stromal cells,” Human Reproduction, vol. 9, no. 12, pp. 2411–2417, 1994. View at Google Scholar · View at Scopus
  145. M. Kariya, H. Kanzaki, K. Takakura et al., “Interleukin-1 inhibits in Vitro decidualization of human endometrial stromal cells,” Journal of Clinical Endocrinology and Metabolism, vol. 73, no. 6, pp. 1170–1174, 1991. View at Google Scholar · View at Scopus
  146. N. Inagaki, L. Ung, T. Otani, D. Wilkinson, and A. Lopata, “Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adenomyosis or endometrial polyp,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 111, no. 2, pp. 197–203, 2003. View at Publisher · View at Google Scholar · View at Scopus
  147. S. Matsuzaki, M. Canis, C. Darcha, J. Pouly, and G. Mage, “HOXA-10 expression in the mid-secretory endometrium of infertile patients with either endometriosis, uterine fibromas or unexplained infertility,” Human Reproduction, vol. 24, no. 12, pp. 3180–3187, 2009. View at Publisher · View at Google Scholar · View at Scopus
  148. B. C. Paria, J. Reese, S. K. Das, and S. K. Dey, “Deciphering the cross-talk of implantation: advances and challenges,” Science, vol. 296, no. 5576, pp. 2185–2188, 2002. View at Publisher · View at Google Scholar · View at Scopus
  149. B. W. Rackow and H. S. Taylor, “Submucosal uterine leiomyomas have a global effect on molecular determinants of endometrial receptivity,” Fertility and Sterility, vol. 93, no. 6, pp. 2027–2034, 2010. View at Publisher · View at Google Scholar · View at Scopus
  150. D. C. Sinclair, A. Mastroyannis, and H. S. Taylor, “Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 2, pp. 412–421, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. K. Y. Lee, J. Jeong, J. Wang et al., “Bmp2 is critical for the murine uterine decidual response,” Molecular and Cellular Biology, vol. 27, no. 15, pp. 5468–5478, 2007. View at Publisher · View at Google Scholar · View at Scopus
  152. E. B. Morosova, A. B. Chukhlovin, N. V. Kulagina, N. V. Kipich, and A. A. Totolian, “Functional gene polymorphism of matrix metalloproteinase-1 is associated with benign hyperplasia of myo- and endometrium in the Russian population,” Genetic Testing and Molecular Biomarkers, vol. 16, no. 9, pp. 1032–1037, 2012. View at Google Scholar